IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
Treatment Strategies for ROS1 Non-Small Cell Lung Cancer
February 06, 2018 | Online

Overview

During this webinar we will: 

  • review ROS1 epidemiology;
  • appraise optimal testing;
  • review treatment results with different ROS inhibitors;
  • identify the mechanisms of acquired resistance to ROS1 inhibitors; and
  • look forward to the potential next steps in the management of this disease.

What you should expect to learn

Learning Objectives:

  • Demonstrate new targetable molecular subtype, ROS1, a distinct group of patients for which new treatments are now available.
  • Appraise optimal molecular testing to determine the profile of individual patients and selection for specific, active therapeutic approaches.
  • Identify the mechanisms of acquired resistance to ROS1 inhibitors.

Federico Cappuzzo, MD

Director of Medical Oncology
Department of Medical 
Oncology and Hematology
Ospedale Santa Maria delle Croci
Ravenna, Italy

&

Enriqueta Felip, MD

Chief Thoracic Medical Oncology
Associate Professor,
Vall d'Hebron University Hospital
Barcelona, Spain

Contact